The oncology treatment landscape is rapidly evolving with over 100 molecules in phase III development, where 68% are targeted agents, indicating increased specialization in oncology. Exceptional launch activity expected over the next four years will offer diverse options across both solid and hematological malignancies, underscoring the need for enhanced stakeholder engagement. Understanding treatment pathways and patient segments is crucial for payers and clinicians amidst the growth of options for patient care.

1. PAGE 2 IMS HEALTH REAL-WORLD EVIDENCE SOLUTIONS
INSIGHTS HOW IS ONCOLOGY TREATMENT EVOLVING?
ACCESSPOINT • VOLUME 6 • ISSUE 12 PAGE 3
20172016 2018 2019 2020 >2020
The Current Oncology Pipeline:
Development & Launch
Exceptional launch activity increases options for patients but requires a greater understanding of treatment
pathways and patient segments for payers and clinicians. The sheer volume of potential new products drives
a need to reassess the way information about these expanded options is conveyed to stakeholders.
These figures are estimates based on phase III completion dates. The actual number of launches will depend on successful trial completion and FDA approval.
Products in phase II that could successfully move through launch are not included.
Intense R&D activity reflects tremendous market growth and an increased
understanding of oncology. Of the 100+ molecules in phase III development,
68% are targeted agents, illustrating how oncology will become even more specialized.
Breast
Cancer
Non-Small Cell
Lung Cancer
80%
10%
10%
Ovarian
Cancer
Acute Myeloid
Leukemia
Gastric
Cancer
8%
46%
23%
23%
66%
17%
17%
66%
17%
17%
80%
20%
50%
50%
Hepatocellular
Carcinoma
Melanoma
38%
49%
7%
3%
3%
75%
25%
68%
26%
100%
Colorectal
Cancer
61%
13%
13%
13%
Renal Cell
Cancer
Non-Hodgkin
Lymphoma
Others
4
66
5 4
19 19 13 8
4 29
6%
57%
11%
26%
2%
2% 2%
11
33
12%
73%3%12%
58
53%
34%
13% 54%
42%
4%
61%
35%
4%
47
24
23
73%
18%
9%
70%20%
10%
47% 53%
83%17%58%
14%
14%
14%
41%
3%
56% 39
10
7 6
2986%7%
7%
20%
15
Launch activity over the next 4 years promises a range of new options
across solid and hematological malignancies
Note: Represents the top 10 tumors by number of launches from 2016-2020
Number of Launches
Acute
Myeloid
Leukemia
47%33% 15
Gastric
Cancer
20%
Hepato-
cellular
Carcinoma
MelanomaBreast
Cancer
80%
10%
10% 10
Ovarian
Cancer
Colorectal
Cancer
100% 8
Chronic
Lymphocytic
Leukemia
100% 10
Non-Hodgkin
Lymphoma
Non-Small
Cell Lung
Cancer
Source all data: IMS R&D Focus; www.clinicaltrials.gov
Vaccine
Targeted
Oncolytic Virus
Immuno-oncology
Others
Chemotherapy
Activity
Breakdown
Unprecedented launches signal new
needs for stakeholder engagement
68%
2%
7%
18%
VaccineImmuno-oncologyTargeted Chemotherapy Oncolytic Virus Other
n=101
Saurabh Kumar, MD, MBA – Senior Manager, Global Delivery Center, IMS Health, Skumar1@in.imshealth.com
Divya Dhingra, MSC – Associate Consultant, IMS Health, Ddhingra@in.imshealth.com
2016 2018 2019 2020 >20202017
3% 2%
Total Clinical
Activity
18%